美股異動丨Moderna盤前漲超5%,用於65歲以上者的下一代新冠疫苗獲批
Moderna(MRNA.US)盤前上漲超5%,此前美國食品藥品監督管理局(FDA)批準該公司面向65歲及以上成人的下一代新冠疫苗。消息面上,美國於5月30日晚批準莫德納(Moderna)公司生產的一款新型低劑量的新冠疫苗,限用於65歲以上成人,以及具有重症高風險的12歲至64歲羣體。據悉,這款疫苗並非用於替代莫德納現有疫苗,而是一種替代選項。這種名爲mNexspike的新疫苗是朝著下一代冠狀病毒疫苗邁出一步。透過改進免疫靶點,此疫苗的製備方法允許降低劑量,僅爲莫德納現有新冠疫苗Spikevax的1/5劑量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.